Literature DB >> 1717983

Acidic fibroblast growth factor promotes vascular repair.

T D Bjornsson1, M Dryjski, J Tluczek, R Mennie, J Ronan, T N Mellin, K A Thomas.   

Abstract

Intravascular injury to arteries can result in thickening of the intimal smooth muscle layer adjacent to the lumen by migration and proliferation of cells from the underlying medial smooth muscle layer accompanied by deposition of extracellular matrix. This pathological response, which decreases lumen diameter, might, in part, be the result of the access of smooth muscle cells to plasma and platelet-derived growth factors as a consequence of denudation of the overlying confluent monolayer of vascular endothelial cells. Injured rat carotid arteries were treated by i.v. administration of acidic fibroblast growth factor, a heparin-binding protein that is chemotactic and mitogenic for vascular endothelial cells. The growth factor treatment resulted in dose-dependent inhibition of intimal thickening with parallel promotion of endothelial regeneration over the injured area. Therefore, acidic fibroblast growth factor might be efficacious in the prevention of restenosis caused by intimal thickening following angioplasty in humans.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1717983      PMCID: PMC52567          DOI: 10.1073/pnas.88.19.8651

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  32 in total

1.  Pure brain-derived acidic fibroblast growth factor is a potent angiogenic vascular endothelial cell mitogen with sequence homology to interleukin 1.

Authors:  K A Thomas; M Rios-Candelore; G Giménez-Gallego; J DiSalvo; C Bennett; J Rodkey; S Fitzpatrick
Journal:  Proc Natl Acad Sci U S A       Date:  1985-10       Impact factor: 11.205

2.  Induction of angiogenesis by bovine brain derived class 1 heparin-binding growth factor.

Authors:  R R Lobb; E M Alderman; J W Fett
Journal:  Biochemistry       Date:  1985-09-10       Impact factor: 3.162

3.  Heparin-binding growth factor-I (endothelial cell growth factor) binds to endothelium in vivo.

Authors:  T K Rosengart; J P Kupferschmid; V J Ferrans; W Casscells; T Maciag; R E Clark
Journal:  J Vasc Surg       Date:  1988-02       Impact factor: 4.268

4.  Human vascular smooth muscle cells both express and respond to heparin-binding growth factor I (endothelial cell growth factor).

Authors:  J A Winkles; R Friesel; W H Burgess; R Howk; T Mehlman; R Weinstein; T Maciag
Journal:  Proc Natl Acad Sci U S A       Date:  1987-10       Impact factor: 11.205

5.  Inhibition of intimal hyperplasia after arterial injury by heparins and heparinoid.

Authors:  M Dryjski; E Mikat; T D Bjornsson
Journal:  J Vasc Surg       Date:  1988-11       Impact factor: 4.268

6.  Significance of quiescent smooth muscle migration in the injured rat carotid artery.

Authors:  A W Clowes; S M Schwartz
Journal:  Circ Res       Date:  1985-01       Impact factor: 17.367

7.  Human endothelial cells are chemotactic to endothelial cell growth factor and heparin.

Authors:  V P Terranova; R DiFlorio; R M Lyall; S Hic; R Friesel; T Maciag
Journal:  J Cell Biol       Date:  1985-12       Impact factor: 10.539

Review 8.  The pathogenesis of atherosclerosis: atherogenesis and inflammation.

Authors:  J M Munro; R S Cotran
Journal:  Lab Invest       Date:  1988-03       Impact factor: 5.662

9.  Role of basic fibroblast growth factor in vascular lesion formation.

Authors:  V Lindner; D A Lappi; A Baird; R A Majack; M A Reidy
Journal:  Circ Res       Date:  1991-01       Impact factor: 17.367

Review 10.  The fibroblast growth factor family: structural and biological properties.

Authors:  M Klagsbrun
Journal:  Prog Growth Factor Res       Date:  1989
View more
  18 in total

1.  Fibroblast growth factor receptor 4 polymorphisms and susceptibility to coronary artery disease.

Authors:  Lan Ma; Haifeng Zhang; Carrie Han; Danian Tong; Meiyan Zhang; Yi'an Yao; Yu Luo; Xuebo Liu
Journal:  DNA Cell Biol       Date:  2012-02-07       Impact factor: 3.311

2.  Molecular atherectomy for restenosis.

Authors:  W Casscells; D A Lappi; A Baird
Journal:  Trends Cardiovasc Med       Date:  1993 Nov-Dec       Impact factor: 6.677

3.  Tissue engineered perivascular endothelial cell implants regulate vascular injury.

Authors:  A Nathan; M A Nugent; E R Edelman
Journal:  Proc Natl Acad Sci U S A       Date:  1995-08-29       Impact factor: 11.205

4.  A potent inhibitor of endothelial cell proliferation is generated by proteolytic cleavage of the chemokine platelet factor 4.

Authors:  S K Gupta; T Hassel; J P Singh
Journal:  Proc Natl Acad Sci U S A       Date:  1995-08-15       Impact factor: 11.205

5.  Involvement of fibroblast growth factor 18 in dedifferentiation of cultured human chondrocytes.

Authors:  H Yamaoka; S Nishizawa; Y Asawa; Y Fujihara; T Ogasawara; K Yamaoka; S Nagata; T Takato; K Hoshi
Journal:  Cell Prolif       Date:  2009-11-10       Impact factor: 6.831

6.  The effect of FGF-1 loaded alginate microbeads on neovascularization and adipogenesis in a vascular pedicle model of adipose tissue engineering.

Authors:  Monica L Moya; Ming-Huei Cheng; Jung-Ju Huang; Megan E Francis-Sedlak; Shu-Wei Kao; Emmanuel C Opara; Eric M Brey
Journal:  Biomaterials       Date:  2010-01-18       Impact factor: 12.479

7.  Endothelial cell migration on RGD-peptide-containing PEG hydrogels in the presence of sphingosine 1-phosphate.

Authors:  Bradley K Wacker; Shannon K Alford; Evan A Scott; Meghna Das Thakur; Gregory D Longmore; Donald L Elbert
Journal:  Biophys J       Date:  2007-09-07       Impact factor: 4.033

8.  Construction and characterization of a thrombin-resistant designer FGF-based collagen binding domain angiogen.

Authors:  Luke P Brewster; Cicely Washington; Eric M Brey; Andrew Gassman; Anu Subramanian; Jen Calceterra; William Wolf; Connie L Hall; William H Velander; Wilson H Burgess; Howard P Greisler
Journal:  Biomaterials       Date:  2007-10-22       Impact factor: 12.479

9.  Identification of an Escherichia coli protein impurity in preparations of a recombinant pharmaceutical.

Authors:  D O O'Keefe; P DePhillips; M L Will
Journal:  Pharm Res       Date:  1993-07       Impact factor: 4.200

10.  Perivascular and intravenous administration of basic fibroblast growth factor: vascular and solid organ deposition.

Authors:  E R Edelman; M A Nugent; M J Karnovsky
Journal:  Proc Natl Acad Sci U S A       Date:  1993-02-15       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.